Merck (MRK) Wins FDA Approval For WELIREG Plus LENVIMA In Kidney Cancer

What happened: Merck (NYSE:MRK) received FDA approval for WELIREG plus LENVIMA in adults with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. Merck also began a first-in-human Phase I trial using Cyprumed's oral peptide delivery platform for an undisclosed peptide candidate. Key numbers: WELIREG 120 mg once daily; LENVIMA 20 mg once daily; $156 fair value cited. Why it matters: The approval supports Merck's post-Keytruda oncology catalyst, while the Cyprumed trial keeps execution risk around newer technologies live until oral peptide delivery advances.

Merck (NYSE:MRK) received FDA approval for WELIREG plus LENVIMA in adults with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. Merck also began a first-in-human Phase I trial using Cyprumed's oral peptide delivery platform for an undisclosed peptide candidate.

The approval supports Merck's post-Keytruda oncology catalyst, while the Cyprumed trial keeps execution risk around newer technologies live until oral peptide delivery advances.